BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 24056704)

  • 1. Effects of ketoconazole and rifampicin on the pharmacokinetics of GLS4, a novel anti-hepatitis B virus compound, in dogs.
    Zhou X; Gao ZW; Meng J; Chen XY; Zhong DF
    Acta Pharmacol Sin; 2013 Nov; 34(11):1420-6. PubMed ID: 24056704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.
    Noh YH; Lim HS; Jin SJ; Kim MJ; Kim YH; Sung HR; Choi HY; Bae KS
    Clin Ther; 2012 May; 34(5):1182-94. PubMed ID: 22534255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study.
    Shin KH; Kim BH; Kim TE; Kim JW; Yi S; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2009 Dec; 31(12):3009-20. PubMed ID: 20110038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of modulation of P-glycoprotein and /or cytochrome P450 3A on the pharmacokinetics and pharmacodynamics of orally administered morphine in dogs.
    Gadeyne C; Van der Heyden S; Gasthuys F; Croubels S; Schauvliege S; Polis I
    J Vet Pharmacol Ther; 2011 Oct; 34(5):417-23. PubMed ID: 21241325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants.
    Tanaka C; Yin OQ; Smith T; Sethuraman V; Grouss K; Galitz L; Harrell R; Schran H
    J Clin Pharmacol; 2011 Jan; 51(1):75-83. PubMed ID: 20702754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist.
    Lee J; Moy S; Meijer J; Krauwinkel W; Sawamoto T; Kerbusch V; Kowalski D; Roy M; Marion A; Takusagawa S; van Gelderen M; Keirns J
    Clin Drug Investig; 2013 Jun; 33(6):429-40. PubMed ID: 23625188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers.
    Dutreix C; Munarini F; Lorenzo S; Roesel J; Wang Y
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1223-34. PubMed ID: 24085261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers.
    Mahatthanatrakul W; Sriwiriyajan S; Ridtitid W; Boonleang J; Wongnawa M; Rujimamahasan N; Pipatrattanaseree W
    J Clin Pharm Ther; 2012 Apr; 37(2):221-5. PubMed ID: 21518375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults.
    Kusawake T; den Adel M; Groenendaal-van de Meent D; Garcia-Hernandez A; Takada A; Kato K; Ohtsu Y; Katashima M
    Adv Ther; 2017 Nov; 34(11):2466-2480. PubMed ID: 29076107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers.
    Garg V; Chandorkar G; Yang Y; Adda N; McNair L; Alves K; Smith F; van Heeswijk RP
    Br J Clin Pharmacol; 2013 Feb; 75(2):431-9. PubMed ID: 22642697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects.
    Xu H; O'Gorman M; Tan W; Brega N; Bello A
    Eur J Clin Pharmacol; 2015 Dec; 71(12):1441-9. PubMed ID: 26381275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycyrrhizin accelerates the metabolism of triptolide through induction of CYP3A in rats.
    Tai T; Huang X; Su Y; Ji J; Su Y; Jiang Z; Zhang L
    J Ethnopharmacol; 2014 Mar; 152(2):358-63. PubMed ID: 24486211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of metabolites of GLS4 in humans using ultrahigh-performance liquid chromatography/quadrupole time-of-flight mass spectrometry.
    Zhou X; Li L; Deng P; Chen X; Zhong D
    Rapid Commun Mass Spectrom; 2013 Nov; 27(21):2483-92. PubMed ID: 24097405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic Interactions of Rolapitant With Cytochrome P450 3A Substrates in Healthy Subjects.
    Wang X; Wang J; Arora S; Hughes L; Christensen J; Lu S; Zhang ZY
    J Clin Pharmacol; 2019 Apr; 59(4):488-499. PubMed ID: 30422319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers.
    Liu Y; Zhou S; Wan Y; Wu A; Palmisano M
    Br J Clin Pharmacol; 2014 Nov; 78(5):1050-7. PubMed ID: 24962564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects.
    Shoaf SE; Bricmont P; Mallikaarjun S
    Br J Clin Pharmacol; 2012 Apr; 73(4):579-87. PubMed ID: 21988334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin.
    Kerbusch T; Jansen RL; Mathôt RA; Huitema AD; Jansen M; van Rijswijk RE; Beijnen JH
    Clin Pharmacol Ther; 2001 Aug; 70(2):132-41. PubMed ID: 11503007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of multiple dosing of ketoconazole on pharmacokinetics of midazolam, a cytochrome P-450 3A substrate in beagle dogs.
    Kuroha M; Azumano A; Kuze Y; Shimoda M; Kokue E
    Drug Metab Dispos; 2002 Jan; 30(1):63-8. PubMed ID: 11744613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies.
    Martin P; Gillen M; Millson D; Oliver S; Brealey C; Grossbard EB; Baluom M; Lau D; Sweeny D; Mant T; Craven K
    Drugs R D; 2016 Mar; 16(1):81-92. PubMed ID: 26739683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide.
    Hatorp V; Hansen KT; Thomsen MS
    J Clin Pharmacol; 2003 Jun; 43(6):649-60. PubMed ID: 12817528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.